ClinicalTrials.gg

Program

faricimab

Also written as “Faricimab”, “Faricimab PFS Configuration” and “RO6867461”.

Its studies are mostly in Macular Edema · Macular Degeneration · Choroidal Neovascularization · Wet Macular Degeneration, led by Hoffmann-La Roche.

Furthest: phase 4, since Jan 25, 202217 company-led studies, 2 open or runningNext primary completion: Jan 26, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche172 open or runningphase 4since Jan 25, 2022Sep 3, 2013Jan 26, 2027phase 4 · NCT05224102

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 3, 2013First study: phase 1 study in Macular DegenerationFirst studyNCT01941082 · 24 enrolled · United States, United Kingdom
  2. Jun 12, 2015Phase 2 study in Choroidal NeovascularizationNCT02484690 · 273 enrolled · United States
  3. Mar 1, 2016Phase 2 study in Diabetic Macular EdemaNCT02699450 · 229 enrolled · United States
  4. Jan 31, 2017Phase 2 study in Choroidal NeovascularizationNCT03038880 · 76 enrolled · United States
  5. Aug 1, 20182 phase 3 studies in Diabetic Macular EdemaNCT03622593, NCT03622580
  6. Jan 29, 20192 phase 3 studies in Wet Macular DegenerationNCT03823300, NCT03823287
  7. Jun 12, 2020Phase 3 study in Diabetic Macular EdemaNCT04432831 · 1,479 enrolled · United States, Argentina, Australia and more
  8. Oct 19, 2020Phase 2 study in Diabetic Macular EdemaNCT04597918 · 99 enrolled · United States, Argentina, Canada and more
  9. Feb 3, 20213 phase 3 studiesNCT04740931, NCT04740905, NCT04777201
  10. Jan 25, 2022Phase 4 study in Diabetic Macular EdemaNCT05224102 · 218 enrolled · United States, India, Kenya and more
  11. Oct 4, 2022Phase 3 study in Neovascular Age-related Macular DegenerationNCT05569148 · 35 enrolled · United States
  12. Dec 11, 2023Phase 3 study in Choroidal Neovascularization Secondary to Pathologic MyopiaNCT06176352 · 280 enrolled · Australia, China, France and more
  13. Jan 24, 2025Phase 4 study in Neovascular Age-related Macular Degeneration (nAMD)NCT06795048 · 274 enrolled · United States, Australia, Canada and more

Ahead

  1. Jan 26, 2027Primary completion: phase 4 study in Diabetic Macular EdemaNCT05224102

TargetBeta

“A humanized bispecific antibody targeting both vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2; Ang2; ANGPT2), that is used for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema”NCIt, by rule
“Angiopoietin-2 inhibitor; Vascular endothelial growth factor A inhibitor”ChEMBL 37, by rule

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06795048Neovascular Age-related Macular Degeneration (nAMD) · United States, Australia, Canada and more4Active, not recruitingOct 16, 2026274
NCT06176352Choroidal Neovascularization Secondary to Pathologic Myopia · Australia, China, France and more3CompletedMay 22, 2026280
NCT05569148Neovascular Age-related Macular Degeneration · United States3CompletedNov 10, 202235
NCT05224102Diabetic Macular Edema · United States, India, Kenya and more4Active, not recruitingJan 26, 2027218
NCT04777201Neovascular Age-related Macular Degeneration · United States, Argentina, Australia and more3CompletedSep 3, 20241,036
NCT04740931Macular Edema · United States, Argentina, Australia and more3CompletedAug 9, 2022729
NCT04740905Macular Edema · United States, Argentina, Australia and more3CompletedJul 6, 2022553
NCT04597918Diabetic Macular Edema · United States, Argentina, Canada and more2CompletedDec 22, 202299
NCT04432831Diabetic Macular Edema · United States, Argentina, Australia and more3CompletedOct 11, 20231,479
NCT03823300Wet Macular Degeneration · United States, Argentina, Australia and more3CompletedOct 5, 2020658
NCT03823287Wet Macular Degeneration · United States, Canada, Germany and more3CompletedOct 26, 2020671
NCT03622593Diabetic Macular Edema · United States, Argentina, Australia and more3CompletedOct 19, 2020951
NCT03622580Diabetic Macular Edema · United States, Austria, Bulgaria and more3CompletedOct 20, 2020940
NCT03038880Choroidal Neovascularization · United States2CompletedJan 11, 201876
NCT02699450Diabetic Macular Edema · United States2CompletedSep 15, 2017229
NCT02484690Choroidal Neovascularization · United States2CompletedSep 26, 2017273
NCT01941082Macular Degeneration · United States, United Kingdom1CompletedFeb 201524

How it is read

Names in the registry

  • “Faricimab”, 15 entries
  • “Faricimab PFS Configuration”, 1 entry
  • “RO6867461”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.